Uzm. Dr. Selver Işık

Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study

BMC Cancer, 2026

DOI 10.1186/s12885-026-15725-9 PMID 41691201 Frei zugänglicher VolltextQuelle: OpenAlex

Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)

Clinical & Translational Oncology, 2026

DOI 10.1007/s12094-026-04494-3 PMID 42400766 Quelle: OpenAlex

Determinants of survival after neoadjuvant chemotherapy in resectable gastric cancer: adjuvant dose intensity, radiotherapy, and pathologic response

Expert Review of Anticancer Therapy, 2026

DOI 10.1080/14737140.2026.2657911 PMID 41950348 Quelle: OpenAlex

Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study

Cancers, 2026

DOI 10.3390/cancers18132127 PMID 42449669 Frei zugänglicher VolltextQuelle: OpenAlex

Prognostic Impact of Early Metabolic Response on Interim 18F-FDG PET/CT in HR+/HER2− Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

Medicina, 2026

DOI 10.3390/medicina62030488 PMID 41901569 Frei zugänglicher VolltextQuelle: OpenAlex

Prognostic impact of the Gustave Roussy Immune score in metastatic renal cell carcinoma treated with first-line immunotherapy-based combinations: results from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

BMC Cancer, 2026

DOI 10.1186/s12885-026-16664-1 Frei zugänglicher VolltextQuelle: OpenAlex

Real-World Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients With Advanced Bone Sarcomas: The TOGBONE Study of the Turkish Oncology Group

JCO Global Oncology, 2026

DOI 10.1200/go-26-00317 PMID 42715501 Frei zugänglicher VolltextQuelle: ORCID

Long-Term Outcomes and Conditional Recurrence-Free Survival in Stage II Colon Cancer: The Impact of Surveillance and Recurrence Detection Strategies

Journal of Clinical Medicine, 2026

DOI 10.3390/jcm15134901 PMID 42452362 Frei zugänglicher VolltextQuelle: ORCID

Prognostic Value of 18F-FDG PET/CT-Derived Secondary Lymphoid Organ Ratios and Hematologic Inflammation Markers in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab

Journal of Clinical Medicine, 2026

DOI 10.3390/jcm15020798 PMID 41598735 Frei zugänglicher VolltextQuelle: ORCID

Prognostic Value of Systemic Immune-Inflammation Index in Mucosal Malignant Melanoma

Journal of Clinical Medicine, 2026

DOI 10.3390/jcm15020890 PMID 41598826 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Prognostic Value of Treatment-Related Body Composition Changes in Metastatic NSCLC Receiving Nivolumab

Medicina, 2026

DOI 10.3390/medicina62010098 PMID 41597384 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Prognostic role of smoking in metastatic renal cell carcinoma in real-world data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

Scientific Reports, 2026

DOI 10.1038/s41598-026-35435-3 PMID 41548007 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

Adult-Onset Diffuse Midline Glioma, H3K27-Altered: A Genomics-Guided, Individualized, Multimodal Treatment Approach

Brain Sciences, 2026

DOI 10.3390/brainsci16010097 PMID 41594818 Frei zugänglicher VolltextQuelle: ORCID

Acquired CD74–ROS1 fusion–mediated osimertinib resistance successfully treated with osimertinib and crizotinib: a case report

Journal of Chemotherapy, 2026

DOI 10.1080/1120009x.2026.2657116 PMID 41992733 2 Zitationen (OpenAlex) Quelle: OpenAlex

Capecitabine-induced pneumonitis: a rare case report and literature review

Anti-Cancer Drugs, 2026

DOI 10.1097/cad.0000000000001839 PMID 42668437 1 Zitation (OpenAlex) Quelle: OpenAlex

Digital health engagement and health literacy among cancer patients: a cross-sectional study of ICT usage patterns

BMC Health Services Research, 2026

DOI 10.1186/s12913-026-15432-y 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

Oncological Perspective on Bone-Metastatic Colorectal Cancer: a Single-Centre Experience

Journal of Gastrointestinal Cancer, 2026

DOI 10.1007/s12029-026-01457-3 PMID 41944932 Quelle: OpenAlex

Comparative overall survival in T4N0 and T2-3N1 non-metastatic colon cancer: a retrospective cohort study

Annals of Saudi Medicine, 2026

DOI 10.5144/0256-4947.2026.169 PMID 42251515 Frei zugänglicher VolltextQuelle: OpenAlex

Baseline and Early On-Treatment Prognostic Nutritional Index in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

Journal of Clinical Medicine, 2026

DOI 10.3390/jcm15176790 PMID 42739793 Frei zugänglicher VolltextQuelle: OpenAlex

Prognostic Value of a Seven-Factor Risk Stratification System in T3N0 Colon Cancer: A Single-Center Retrospective Study

Medicina, 2026

DOI 10.3390/medicina62101846 PMID 42942377 Frei zugänglicher VolltextQuelle: OpenAlex

Healthy Lifestyle Behaviors and Health Literacy in Oncology Patients: Evaluation of Organic Food Consumption and Physical Activity

Eurasian Journal of Medical Investigation, 2026

DOI 10.14744/ejmi.269303 Quelle: OpenAlex

Real-life Comparison of FOLFOX-6 and Modified DCF Regimens for the First-Line Treatment of HER-2 Negative Metastatic Gastric Cancer

Eurasian Journal of Medical Investigation, 2026

DOI 10.14744/ejmi.269337 Quelle: ORCID

Prognostic value of nutritional and inflammation-based scores in advanced soft tissue sarcoma treated with trabectedin: a multicenter study

Frontiers in Oncology, 2026

DOI 10.3389/fonc.2026.1820227 PMID 42109666 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

Prognostic Factors in High Grade Osteosarcoma Patients Who Received Neoadjuvant Therapy and Subsequently Underwent Surgery: Data from the Turkish Oncology Group

Journal of Clinical Medicine, 2025

DOI 10.3390/jcm14062024 PMID 40142832 16 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Evaluation of Dose Reduction Factors and Impact on Progression-Free Survival in Patients Treated with CDK 4/6 Inhibitors

Journal of Clinical Medicine, 2025

DOI 10.3390/jcm14041071 PMID 40004601 9 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium

癌症：英文版, 2025

DOI 10.1002/cac2.70003 PMID 39927571 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

The impact of smoking on nivolumab outcomes in renal cell carcinoma: real-world data from the Turkish Oncology Group Kidney Cancer Consortium

The Oncologist, 2025

DOI 10.1093/oncolo/oyaf186 PMID 40577354 Frei zugänglicher VolltextQuelle: OpenAlex

Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study

Immunotherapy, 2025

DOI 10.1080/1750743x.2025.2527019 PMID 40611593 Frei zugänglicher VolltextQuelle: OpenAlex

Sorafenib vs chemotherapy in the treatment of locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: real-world data from Turkey

Journal of Chemotherapy, 2025

DOI 10.1080/1120009x.2024.2430845 PMID 39588941 1 Zitation (Europe PMC) Quelle: ORCID

The Role of Baseline PET/CT Parameters in Predicting Treatment Response in Patients with Locally Advanced Rectal Cancer Undergoing Total Neoadjuvant Therapy

Medicina, 2025

DOI 10.3390/medicina61081449 PMID 40870493 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study

Turkish Journal of Clinics and Laboratory, 2025

DOI 10.18663/tjcl.1575691 Frei zugänglicher VolltextQuelle: ORCID

Oncological perspective on Kaposi sarcoma: A single-centre experience

Marmara Medical Journal, 2025

DOI 10.5472/marumj.1627569 Frei zugänglicher VolltextQuelle: ORCID

Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

Clinical and Translational Oncology, 2025

DOI 10.1007/s12094-024-03813-w PMID 39812937 6 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma

BMC Cancer, 2025

DOI 10.1186/s12885-025-14654-3 PMID 40713516 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium

Therapeutic Advances in Medical Oncology, 2025

DOI 10.1177/17588359251331540 PMID 40297625 Frei zugänglicher VolltextQuelle: ORCID

The Effect of Systemic Inflammation and Clinicopathologic Features on Survival in Malignant Pleural Mesothelioma: A Multicenter Analysis

Medicina, 2025

DOI 10.3390/medicina61010144 PMID 39859125 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Clinical and Demographic Features in Malignant Peritoneal Mesothelioma: Treatment Approaches and Factors Affecting Survival

Journal of Oncological Sciences, 2025

DOI 10.37047/jos.galenos.2025.2025-3-18 Frei zugänglicher VolltextQuelle: OpenAlex

Prognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Overall and Elderly Populations

Medicina, 2025

DOI 10.3390/medicina61071160 PMID 40731790 7 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

Clinicopathological features and treatment outcomes of patients with fibrolamellar hepatocellular carcinoma: a retrospective multicenter study

Annals of Saudi Medicine, 2025

DOI 10.5144/0256-4947.2025.249 PMID 40753462 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

Impact of Sarcopenia and Osteopenia on Prognosis in Metastatic Biliary Tract Cancer: A Single Center Experience

Nutrition and Cancer, 2025

DOI 10.1080/01635581.2025.2496371 PMID 40327413 1 Zitation (OpenAlex) Quelle: OpenAlex

Colorectal Cancer Metastasizing to the Thyroid Gland: A Rare and Interesting Case

Journal of Oncological Sciences, 2025

DOI 10.37047/jos.galenos.2025.2025-3-11 Frei zugänglicher VolltextQuelle: OpenAlex

Impact of renin angiotensin system inhibitors on survival of patients with metastatic non-small cell lung cancer.

PubMed Central, 2025

DOI 10.5144/0256-4947.2025.18 PMID 39929787 6 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

Sex-related disparities in outcomes of survival in biliary tract cancer patients

Journal of Cancer Research and Clinical Oncology, 2025

DOI 10.1007/s00432-025-06096-y PMID 40016575 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

Denovo Metastatic Primary Gastric Ewing Sarcoma/Primitive Neuroectodermal Tumor– 13 Years Follow-up: Case Report and Review of Literature

Journal of Medicine and Medical Studies, 2025

DOI 10.51219/jmms/guren-ak/19 Frei zugänglicher VolltextQuelle: OpenAlex

Prognostic implications of cancer-associated fibroblasts and desmoplastic reaction in stage III colon cancer risk groups

Future Oncology, 2025

DOI 10.1080/14796694.2025.2567845 PMID 41047636 Frei zugänglicher VolltextQuelle: OpenAlex

Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

Scientific Reports, 2024

DOI 10.1038/s41598-024-56046-w PMID 38461209 16 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing

Journal of Chemotherapy, 2024

DOI 10.1080/1120009x.2024.2305066 PMID 38263804 2 Zitationen (Europe PMC) Quelle: OpenAlex

Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

Clinical Genitourinary Cancer, 2024

DOI 10.1016/j.clgc.2024.102282 PMID 39709686 2 Zitationen (Europe PMC) Quelle: OpenAlex

Clinicopathologic Features and Efficacy of Induction Chemotherapy in Nasopharyngeal Carcinoma: Real-World Experience

Oncology Research and Treatment, 2024

DOI 10.1159/000537988 PMID 38565096 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Prognostic value of psoas muscle index in metastatic renal cell carcinoma patients treated with anti-VEGF therapy

Indian journal of cancer, 2024

DOI 10.4103/ijc.ijc_649_21 PMID 39960709 Frei zugänglicher VolltextQuelle: Europe PMC